Verification of surface contamination of Japanese cyclophosphamide vials and an example of exposure by handling

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 2, 2012, Pages 201-206

  Hama, Koji ^a   Fukushima, Koichi ^a   Hirabatake, Masaki ^a   Hashida, Tohru ^a   Kataoka, Kazusaburo ^b  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Cyclophosphamide; exposure; urine samples; vial surface contamination; wipe test

Indexed keywords

CYCLOPHOSPHAMIDE;

ARTICLE; DRUG CONTAMINATION; HUMAN; JAPAN; MATERIALS HANDLING; PHARMACIST; PRIORITY JOURNAL; URINALYSIS;

CYCLOPHOSPHAMIDE; DRUG PACKAGING; ENVIRONMENTAL MONITORING; HUMANS; JAPAN; OCCUPATIONAL EXPOSURE; PHARMACISTS; REPRODUCIBILITY OF RESULTS; SURFACE PROPERTIES;

EID: 84871786624     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211419543     Document Type: Article

References (25)

1. Falck K, Göhn P, Sorsa M, Vaino H, Heinonen E, Holsti LR. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet. 1979 ; 313: 1250-1251
2. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in Health Care Settings 2004. DHHS (NIOSH) Publication No. 2004165.
3. Safe handling of cytotoxics. J Oncol Pharm Pract. 2007 ; 13: 1-81
4. Yabunaka H, Sakaguchi F, Kobayashi Y, Nakanishi H. Investigation on vaporization of solution of Endoxan. Jpn J Pharm Health Care Sci. 2010 ; 36: 343-346
5. Connor TH, Shults M, Fraster MP. Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 C and 37 C using a desiccator technique. Mutat Res. 2000 ; 470: 85-92
6. Kiffmeyer TK, Kube C, Opiolka S, Schimidt KG, Schöppe G, Sessink PJM. Vapor pressures, evaporation behavior and airborne concentrations of hazardous drugs: implications for occupational safety. Pharm J. 2002 ; 268: 331-337
7. Tanimura M, Yamada K, Sugiura S, Mori K, Nagata H, Tadokoro K, et al. An environmental and biological study of occupational exposure to cyclophosphamide in the pharmacy of a Japanese community hospital designated for the treatment of cancer. J Health Sci. 2009 ; 55: 750-756
8. Hama T, Aoyama T, Shirai T, Higuchi S, Yokokawa T, Sugimoto Y. Environmental contamination due to preparation of cyclophosphamide and exposure of pharmacists to it. Jpn J Pharm Health Care Sci. 2009 ; 35: 693-700
9. Wick C, Slawson MH, Jorgenson JA, Tyler LS. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health-Syst Pharm. 2003 ; 60: 2314-2320
10. Connor TH, Anderson RW, Sessink PJM, Broadfield L, Power LA. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health-Syst Pharm. 1999 ; 56: 1427-1432
11. Zeedijk M, Greijdanus B, Steenstra FB, Uges DRA. Monitoring exposure of cytostatics on the hospital ward: measuring surface contamination of four different cytostatic drugs from one wipe sample. EJHP-Sci. 2005 ; 11: 18-22
12. McDevitt JJ, Lees PSJ, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993 ; 35: 57-60
13. Schierl R, Herwig A, Pfaller A, Groebmair Fischer E. Surface contamination of antineoplastic drug vials: Comparison of unprotected and protected vials. Am J Health-Syst Pharm. 2010 ; 67: 428-429
14. Nabeshima T, Shoji T, Sugiura S, Tanimura M, Nakao M, Nakanishi H, et al. Guidelines for aseptic preparation of injectable and antineoplastic drugs. J Jpn Soc Hosp Pharm EDS. 2008 ; 44: 18-20
15. Connor TH, Sessink PJM, Harrison BR, Pretty JR, Peters BG, Alfaro RM, et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health-Syst Pharm. 2005 ; 62: 475-484
16. Sessink PJM, Boer KA, Scheefhals APH, Anzion RBM, Bos RP. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosphamide in urine of exposed workers. Int Arch Occup Environ Health. 1992 ; 64: 105-112
17. Sessink PJM, Anzion RBM, van den Broek PH, Bos RP. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 1992 ; 14: 16-22
18. Spivey S, Connor TH. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional iv drug preparation with a closed system. Hosp Pharm. 2003 ; 38: 135-139
19. Sessink PJM, Rolf ME, Rydén NS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999 ; 34: 1311-1317
20. Vandenbroucke J, Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Practice. 2001 ; 6: 146-152
21. Connor TH, Anderson RW, Sessink PJ, Spivey SM. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health-Syst Pharm. 2002 ; 59: 68-72
22. Yoshida J, Tei G, Mochizuki C, Masu Y, Koda S, Kumagai S. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann Occup Hyg. 2009 ; 53: 153-160
23. Bagley CM, Bostick FW, DeVita VT. Clinical pharmacology of cyclophosphamide. Cancer Res. 1973 ; 33: 226-233
24. Hirst M, Mills DG, Tse S, Levin L, White D. Occupational exposure to cyclophosphamide. Lancet. 1984 ; 323: 186-188
25. Sessink PJM, Van den Kerkhof MCA, Anzion RBM, Noordhoek J, Bos RP. Environment contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposure pharmacy technicians: Is skin absorption an important exposure route?. Arch Environ Health. 1994 ; 49: 165-169